LAUREN ARMINGTON: Open Payments
NPI 1245611326 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,179 in 109 payments from 18 companies in 2025. Trend: 2023 $2,226 · 2024 $1,589 · 2025 $2,179
Food & beverage: $2,079Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $442 |
| Regeneron Healthcare Solutions, Inc. | 12 | $274 |
| GENZYME CORPORATION | 12 | $244 |
| Mallinckrodt Hospital Products Inc. | 6 | $235 |
| GlaxoSmithKline, LLC. | 16 | $217 |
| Insmed, Inc. | 11 | $142 |
| PFIZER INC. | 7 | $131 |
| Grifols USA, LLC | 4 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $68 |
Products named: DUPIXENT, ACTHAR, FASENRA, TEZSPIRE, NUCALA, ELIQUIS, Prolastin-C Liquid, GLASSIA.
Industry payments across IN — which companies pay providers there.
